Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the  Genetic Metabolic Dieticians International Conference
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
AMN Healthcare Announces First Quarter 2022 Results
AMN Healthcare Announces First Quarter 2022 Results


AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2022 financial

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and first quarter 2022 financial results.



“This quarter, we have continued to

Puma Biotechnology Reports First Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports First Quarter 2022 Financial Results


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2022. Unless otherwise stated, all comparisons are for the

Xencor Reports First Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports First Quarter 2022 Financial Results


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial

Acadia Healthcare to Present at May Conferences: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare to Present at May Conferences


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at two healthcare conferences in May.



On Wednesday, May 11, 2022, the Company will present at the BofA

Evolva shareholders approve all proposed resolutions at the Annual General Meeting 2022
Evolva shareholders approve all proposed resolutions at the Annual General Meeting 2022
Evolva shareholders approve all proposed resolutions at the Annual General Meeting 2022
U.S. FDA Renews Annual DILIsym Software Licenses for 2022: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
U.S. FDA Renews Annual DILIsym Software Licenses for 2022


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that the U.S. Food and Drug

Premier Inc. to Participate in BofA Securities 2022 Healthcare Conference on May 10, 2022: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc. to Participate in BofA Securities 2022 Healthcare Conference on May 10, 2022


Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, announced today that members of its management team are scheduled to participate in a fireside chat at the

Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference


Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the BofA Securities 2022 Healthcare Conference on Wednesday

Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
QIAGEN führt CE-IVD-zertifizierten HSV-1/2-Herpes-Test zum Einsatz auf dem integrierten PCR-Testsystem NeuMoDx ein
QIAGEN führt CE-IVD-zertifizierten HSV-1/2-Herpes-Test zum Einsatz auf dem integrierten PCR-Testsystem NeuMoDx ein


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass sein Test NeuMoDx HSV 1/2 Quant die CE-IVD-Kennzeichnung für die Europäische Union sowie für Länder, in denen diese

QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System
QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its NeuMoDx HSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1 (HSV-1) DNA

Edison Investment Research Limited: Basilea Pharmaceutica (BSLN): Renewed focus on anti-infectives
Edison Investment Research Limited: Basilea Pharmaceutica (BSLN): Renewed focus on anti-infectives
Edison Investment Research Limited: Basilea Pharmaceutica (BSLN): Renewed focus on anti-infectives
Pharnext: The Latest Findings From CMT&Me, a ‘Real-World’ Digital Lifestyle Study on Charcot-Marie-Tooth Diseases (‘CMTs’), to be Presented at the 2022 Peripheral Nerve Society (‘PNS’) Annual Meeting
Pharnext: The Latest Findings From CMT&Me, a ‘Real-World’ Digital Lifestyle Study on Charcot-Marie-Tooth Diseases (‘CMTs’), to be Presented at the 2022 Peripheral Nerve Society (‘PNS’) Annual Meeting
Pharnext: The Latest Findings From CMT&Me, a ‘Real-World’ Digital Lifestyle Study on Charcot-Marie-Tooth Diseases (‘CMTs’), to be Presented at the 2022 Peripheral Nerve Society (‘PNS’) Annual Meeting
NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022


Regulatory News:



NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities

Quidel Reports First Quarter 2022 Financial Results
Quidel Reports First Quarter 2022 Financial Results


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first

STAAR Surgical Reports Record First Quarter Net Sales of $63.2 Million Up 25% Y/Y: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical Reports Record First Quarter Net Sales of $63.2 Million Up 25% Y/Y


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the

Poxel Announces Availability of Its 2021 Universal Registration Document: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces Availability of Its 2021 Universal Registration Document


POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including

Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs


Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2022, and provided an update on the Company’s clinical development programs and regulatory and

Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results


Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update.



“We have made significant progress on

Charles River Laboratories Announces First-Quarter 2022 Results: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Announces First-Quarter 2022 Results


Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2022. For the quarter, revenue was $913.9 million, an increase of 10.8% from $824.6

LivaNova Reports First-Quarter 2022 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova Reports First-Quarter 2022 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2022.



Financial Summary and Highlights1